Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

Aim:  To compare the efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and inadequate glycaemic control [haemoglobin A1c (HbA1c) ≥ 6.5 and ≤10%] on metformin monotherapy.

[1]  J. Holst,et al.  Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[2]  R. DeFronzo.  Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[3]  M. Nauck,et al.  Incretins and their analogues as new antidiabetic drugs. , 2003, Drug news & perspectives.

[4]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[5]  C. Cobelli,et al.  Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes , 2007, Diabetes, obesity & metabolism.

[6]  R. Schwartz,et al.  Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. , 1998, The Journal of clinical endocrinology and metabolism.

[7]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[8]  M. D. Epstein.  The Benefit of Increasing Sulfonylurea Dose , 1993, Annals of Internal Medicine.

[9]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[10]  H. Yki-Järvinen.  Fat in the liver and insulin resistance , 2005, Annals of medicine.

[11]  W. Zeng,et al.  Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses , 2005, Clinical pharmacology and therapeutics.

[12]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[13]  C. Bailey,et al.  Oral antidiabetic agents: current role in type 2 diabetes mellitus. , 2005, Drugs.

[14]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[15]  Ronald Brazg,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2006, Clinical therapeutics.

[16]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[17]  S. Inzucchi,et al.  Metformin: new understandings, new uses. , 2003, Drugs.

[18]  Douglas G Altman,et al.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.

[19]  M. Hanefeld,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus , 2006, Diabetologia.

[20]  W. Zeng,et al.  Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. , 2006, Clinical Therapeutics.

[21]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[22]  D. Drucker.  Biological actions and therapeutic potential of the glucagon-like peptides. , 2002, Gastroenterology.

[23]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[24]  D A Follmann,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans , 2022 .

[25]  A. Tura,et al.  Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders. , 2003, American journal of physiology. Endocrinology and metabolism.

[26]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[27]  S. M. Setter,et al.  Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. , 2003, Clinical therapeutics.

[28]  M. Riddle.  Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. , 2005, Endocrinology and metabolism clinics of North America.